Navigation Links
Mesoblast Receives Clearance to Begin First European Trial of Allogeneic or 'Off-The-Shelf' Stem Cell Treatment for Heart Attacks
Date:9/5/2011

MELBOURNE, Australia, Sept. 5, 2011 /PRNewswire/ -- Global regenerative medicine company, Mesoblast Limited, (ASX: MSB), today announced that it had received clearance from the European Medicines Agency (EMA) to begin a 225-patient multi-center Phase 2 clinical trial in Europe for its lead cardiovascular product Revascor(TM) in conjunction with angioplasty and stent procedures to prevent heart failure after a major heart attack. Revascor(TM) is an allogeneic, or "off-the-shelf", adult stem cell product derived from Mesoblast's proprietary Mesenchymal Precursor Cell (MPC) platform technology which is being developed for use in a range of cardiovascular diseases including congestive heart failure, chronic angina, and heart attacks (acute myocardial infarction).

The placebo-controlled Phase 2 trial, AMICI (Allogeneic Mesenchymal precursor cell Infusion in myoCardial Infarction), is approved under Europe's voluntary harmonization procedure and will initially recruit patients at multiple European sites, including in the United Kingdom, The Netherlands and Belgium. Trial recruitment is subsequently expected to involve sites in additional European nations, Australia, and the United States. The primary endpoint of the study will be safety and efficacy at six months in heart attack patients who will receive either Revascor(TM) at one of two doses or placebo. Durability of effect will additionally be monitored for up to 36 months.

Heart attacks remain the biggest killer of people in the industrialized world. Every year, over 1.7 million people have a heart attack in Europe, and over 1.1 million in the United States. Most of these patients undergo an early angioplasty of the blocked artery accompanied by implantation of a metal stent to keep the artery open long-term. However, a significant number of the surviving patients subsequently become disabled with heart failure.

Revascor(TM) is injected by a simple intracoronary infusion at the same time as the
'/>"/>

SOURCE Mesoblast
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lupin Receives Final Approval to Market Generic Ultram® ER
2. Assured Pharmacy, Inc. Receives Gross Proceeds of $400,000 from Sale of Convertible Debentures and Warrants
3. Masimo Pronto-7™ Receives Japanese and Canadian Regulatory Clearances
4. Linagliptin Receives Approval in Europe for the Treatment of Type 2 Diabetes
5. Simceres Iremod Receives SFDA New Drug Approval
6. PSI-938 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
7. WuXi AppTec Bioanalytical Services Unit Receives GLP Certificate from OECD and EU
8. Abbott Receives CE Mark for Healon EndoCoat Protective Gel for Cataract Surgery
9. CoLucid Pharmaceuticals Receives Clearance for Investigational New Drug (IND) Application for Lasmiditan for the Treatment of Acute Migraine
10. Inhibikase Therapeutics Receives FDA Clearance for Phase II Trial of IkT-001 to Treat JC Virus Infection, the Cause of Progressive Multifocal Leukoencephalopathy (PML) in Multiple Sclerosis Patients
11. INNOPHARMA Receives FDA Approval of Generic Levetiracetam Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... Aug. 19, 2014 Research and Markets ... Type of Material, by Technology, by Application & by Region- ... offering. The demand for membranes is estimated ... the market to $29.31 billion Membrane technology was ... such as water filtration and kidney dialysis. In modern times, ...
(Date:8/19/2014)... , Aug. 19, 2014 Avizia, Inc., ... that it has closed an equity financing round led ... Middleland Capital. The new funding will be used to ... this financing round, Avizia welcomes Edward Kennedy , ... of directors. He joins Leonard Kurtzman , CFO ...
(Date:8/19/2014)... Calif. , Aug. 19, 2014  Cardiva Medical, ... two tranches of a $16.5 million Series 3 private ... with GE Capital. The Company will use the proceeds ... facility to expand commercial efforts for its VASCADE® Vascular ... . Investing in Series 3 private ...
Breaking Medicine Technology:Global Membranes (MF, RO, UF, Gas Separation, Dialysis, NF) Market - Forecasts to 2019 2Avizia Closes Funding Round 2Cardiva Medical, Inc. Announces Completion of the first two tranches of Series 3 Private Equity Financing and the Closing of a Senior Secured Debt Facility with GE Capital 2
... Inhibitex, Inc. (Nasdaq: INHX ) today announced that ... its common stock, at a purchase price of $4.10 per ... proceeds to Inhibitex from the sale of the shares, after ... to be approximately $44 million.  Inhibitex has granted the underwriters ...
... April 7, 2011 Vystar® Corporation ... Rubber Latex (NRL), a patented, all-natural raw latex ... non-rubbers found in natural rubber latex, has appointed ... (Logo: http://photos.prnewswire.com/prnh/20100203/CL48049LOGO) Ms. Kearney is ...
Cached Medicine Technology:Inhibitex Prices $47 Million Public Offering 2Inhibitex Prices $47 Million Public Offering 3Vystar® Corporation Appoints Joanne Kearney as Vice President of Marketing 2Vystar® Corporation Appoints Joanne Kearney as Vice President of Marketing 3
(Date:8/20/2014)... Mass., (PRWEB) August 20, 2014 ... new report, PHOTONIC SENSORS AND DETECTORS: TECHNOLOGIES ... and detectors market is expected to grow to ... annual growth rate (CAGR) of 15.9%. Increasing ... region. , With a rapidly expanding range of ...
(Date:8/20/2014)... The Institute for Integrative Nutrition ... to announce its new partnership with California ... university offering graduate programs featuring flexible learning. Graduates ... now eligible to receive six graduate credits towards ... , “I’m so thrilled to announce this new ...
(Date:8/20/2014)... One Call Alert expands its line of personal emergency response ... device that connects customers to the help they need with ... 365 days a year. , ResCube can go anywhere—whether inside ... the T-Mobile nationwide network like a cell phone, so it ... with the other One Call Alert systems, ResCube wearers create ...
(Date:8/20/2014)... 19, 2014 (HealthDay News) -- Taking the ... of dying from heart-related causes, a new study suggests. ... year, the findings require urgent confirmation, said the Danish ... actual risk is small and that guidelines for the ... more information is available. One heart expert wasn,t ...
(Date:8/20/2014)... Plymouth University to be an official charity partner. Brain ... awareness of, and funding for, scientific research into brain ... A range of events and activities organised by the ... of staff and students, as well as other University ... The involvement of the wider community across the South ...
Breaking Medicine News(10 mins):Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 2Health News:Integrative Nutrition Announces New Partnership with California Institute of Integral Studies 3Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 2Health News:One Call Alert Introduces ResCube™, Smallest Mobile Medical Alert System on Market 3Health News:Antibiotic Might Raise Heart Risks for Some 2Health News:Plymouth University chooses Brain Tumour Research as official charity 2
... Tenn., Dec. 16 Healthcare Management Systems,Inc.(R) (HMS) announced ... supply a full system of integrated clinical and financial ... their new, integrated HMS,system reinforces their commitment to providing ... Kimball Health Services has some healthcare ...
... reports that at its Annual General Meeting held today, shareholders overwhelmingly approved all of ... , , All seven Board members were re-elected ... , , , Donald H. Segal ... Officer, Kenneth A. Cawkell Director and Corporate ...
... this season of giving and sharing, St.,David,s Community Health ... million in grants to area nonprofit organizations that provide,access ... "Especially this year, we are ... for Central Texans," said Earl Maxwell, CEO of St. ...
... the largest privately held spinal implant manufacturer in the ... as Chief Financial Officer. Ms. DiCicco brings extensive experience ... manufacturer to the executive team at Globus. For the ... Nash Corporation (Nasdaq: KNSY ), a leading ...
... Inc.,(NYSE: STI ) announced today a ... take control of their healthcare costs. The,SunTrust Health ... a healthcare payment card, integrated account,management, online healthcare ... trusted custodial partner. , ...
... 2009 issue, The Journal of Nuclear Medicine SNM,s ... "This change to the publication allows the generous ... and organization of research reports," said Heinrich R. Schelbert, ... Nuclear Medicine . "Most important and critical, it strengthens ...
Cached Medicine News:Health News:Kimball Health Services Selects HMS to Provide Information Technology Infrastructure 2Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 2Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 3Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 4Health News:Helix BioPharma Reports on 2008 Annual General Meeting and Provides Corporate Update 5Health News:$5.15 Million Provided to Support Local Health Care Needs 2Health News:$5.15 Million Provided to Support Local Health Care Needs 3Health News:$5.15 Million Provided to Support Local Health Care Needs 4Health News:Globus Medical Strengthens Executive Team with Appointment of CFO 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 2Health News:SunTrust Introduces Health Savings Accounts for Employers Seeking to Take Control of Healthcare Costs 3Health News:Journal of Nuclear Medicine premiers new, full-color design 2
... design and reduced dimensions provide ... control of IOL while grasping ... the optic. Curved shafts with ... curved. Smooth, flat, cross action ...
... implanting the haptic loop beneath the ... bag without wrist twisting. Angled 45 ... placed in the same vertical plane ... action handle with dull finish. Most ...
Smooth colibri tip used to grasp and subsequently retract the capsule during nucleus delivery. Serrated handle with polished finish....
Two rows of teeth on jaws provide a firm purchase on the nucleus fragment for removal. Flat handle with dull finish....
Medicine Products: